(R)-1-Aminoindane
| Clinical data | |
|---|---|
| Other names | (R)-1-Aminoindan; (R)-(–)-1-Aminoindan; (R)-AI; (R)-1-AI; TVP-136; TV-136; (R)-(−)-1-Indanamine |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C9H11N |
| Molar mass | 133.194 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
(R)-1-Aminoindane ((R)-1-AI; developmental code name TVP-136 or TV-136), or (R)-1-aminoindan, is the major metabolite of the selective MAO-B inhibitor and antiparkinsonian agent rasagiline ((R)-N-propargyl-1-aminoindane).[1] In contrast to rasagiline, it lacks significant monoamine oxidase inhibition.[2][3] In addition, unlike selegiline and its amphetamine metabolites, it lacks monoamine reuptake-inhibiting and -releasing activities and associated amphetamine-like psychostimulant effects.[2][3][4] However, (R)-1-aminoindane retains neuroprotective effects and certain other activities.[2][3][4][5][6]
- ^ Cite error: The named reference
PinterovaHorsleyPalenicek2017was invoked but never defined (see the help page). - ^ a b c Cite error: The named reference
ChenSwope2005was invoked but never defined (see the help page). - ^ a b c Cite error: The named reference
Müller2014was invoked but never defined (see the help page). - ^ a b Cite error: The named reference
SchapiraBateKirkpatrick2005was invoked but never defined (see the help page). - ^ Cite error: The named reference
BrandtBraithwaite2013was invoked but never defined (see the help page). - ^ Cite error: The named reference
SpeiserLevyCohen1998was invoked but never defined (see the help page).